Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to ... and will evaluate the efficacy, safety, and immunogenicity of mRNA-1403 across two seasons.

Since the market is focusing on the COVID vaccine performance and overlooking the revenue opportunity that Moderna's product ... if the treatment efficacy in these studies is in line with the ...

Moderna has also filed for approval for a combination Covid-flu shot. And the company anticipates efficacy data this year from late-stage studies of vaccines for seasonal flu and norovirus ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

The pivotal Phase 3 study of Moderna's CMV vaccine candidate (mRNA-1647) is fully enrolled and accruing cases, evaluating its efficacy, safety and immunogenicity in the prevention of primary ...

the technology used in the Moderna and Pfizer shots, the researchers said. In clinical trials, J&J's vaccine had shown an 85% efficacy. In subsequent studies in the general population, this figure ...

Next-generation COVID-19 vaccine: Moderna shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283) at its 2024 R&D Day event.